Company DescriptionAuxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. It offers cannabis products under various forms, including vape catridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy under the brands KOLAB PROJECT, Dosecann, BACK FORTY, and Foray. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Toronto, Canada.

How the Company Makes Money

Auxly Cannabis Group Financial Statement Overview

Summary

Auxly Cannabis Group is showing improvements with revenue growth and stronger cash flow positions. Despite these advancements, the company faces ongoing net losses, impacting overall profitability. Improvements in equity position and free cash flow indicate better financial management, but challenges in achieving consistent profitability persist.

Income Statement

Neutral

Auxly Cannabis Group has shown a positive revenue growth trend, with a recent increase from $101 million in 2023 to $122 million in 2024. However, despite improved gross profit margins, the company is still experiencing net losses, which affects the net profit margin negatively. The EBITDA margin has turned positive, indicating some operational improvements, but the absence of EBIT margin due to zero EBIT is a concern.

Balance Sheet

Neutral

The company has improved its equity position, with shareholder equity increasing significantly from 2023 to 2024. The debt-to-equity ratio has improved as well, indicating better leverage management. However, the equity ratio shows room for improvement, reflecting moderate financial stability amidst high total liabilities.

Cash Flow

Positive

Auxly Cannabis Group has exhibited strong free cash flow growth, with free cash flow growing from $6.61 million in 2023 to $14.02 million in 2024. The operating cash flow to net income ratio is positive, showing that the company is generating cash from operations despite net losses. The improvement in free cash flow to net income ratio reflects better cash flow management.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
122.33M	101.08M	94.47M	83.83M	50.80M
	Gross Profit
59.93M	21.28M	17.92M	19.29M	11.14M
	EBIT
14.71M	-19.00M	-46.79M	-42.01M	-54.03M
	EBITDA
24.38M	-10.82M	-93.40M	-13.64M	-57.18M
	Net Income Common Stockholders
-16.35M	-44.51M	-130.29M	-45.91M	-87.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
18.50M	15.75M	14.78M	14.89M	21.50M
	Total Assets
261.53M	261.90M	331.82M	450.42M	378.96M
	Total Debt
68.47M	159.04M	193.59M	190.10M	124.68M
	Net Debt
50.12M	143.44M	178.96M	175.35M	103.47M
	Total Liabilities
145.87M	210.86M	246.13M	242.31M	187.43M
	Stockholders Equity
115.66M	51.05M	90.41M	212.52M	195.94M
Cash Flow		Free Cash Flow
14.02M	6.61M	-11.67M	-50.01M	-53.86M
	Operating Cash Flow
16.78M	8.21M	-2.48M	-49.63M	-33.13M
	Investing Cash Flow
-445.00K	-1.56M	1.18M	17.33M	-14.53M
	Financing Cash Flow
-13.59M	-5.68M	1.18M	26.40M	24.74M

Auxly Cannabis Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CBWTF		$76.92M	4.96	18.60%	―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
OGI		$181.34M	19.85	4.76%	―	―	―
MEDIF		$24.28M	―	-16.22%	―	―	―
DBCCF		$29.51M	3.10	20.78%	―	―	―
HLS	60 Neutral	C$155.64M	―	-23.05%	―	-3.73%	32.70%
MILFF		$17.64M	18.83	6.18%	―	―	―

* Healthcare Sector Average

Performance Comparison

CBWTF

Auxly Cannabis Group

0.06

0.04

200.00%

OGI

OrganiGram Holdings

1.35

-0.24

-15.09%

MEDIF

MediPharm Labs

0.06

0.00

0.00%

DBCCF

Decibel Cannabis Company

0.05

0.00

0.00%

TSE:HLS

HLS Therapeutics Inc

4.92

1.37

38.59%

MILFF

1CM Inc

0.19

-0.28

-59.57%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.